Research Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway is frequently overactivated in many solid tumors, including hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) breast cancer. In the...
Read MoreResearch Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor ibrutinib, though effective, has been associated with cardiac toxicity, including atrial fibrillation, heart failure, and sudden death. Acalabrutinib, a second-generation, more selective...
Read MoreResearch Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is one of the most prevalent malignancies in the United States. The American Joint Committee on Cancer (AJCC) staging system remains the cornerstone of risk stratification, but outcomes vary widely among...
Read MoreResearch Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth most common cancer in the United States. Traditional prognostic assessment relies on clinicopathologic features such as Breslow thickness, ulceration status, and mitotic rate, but these factors do not always accurately...
Read MoreResearch Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor α, a nuclear hormone receptor that regulates transcriptional pathways promoting tumor growth and survival. Endocrine therapies targeting ER, including selective estrogen receptor modulators (SERMs), aromatase inhibitors, and selective estrogen receptor...
Read MoreResearch Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CAR-T) therapy that has transformed outcomes for patients with relapsed or refractory multiple myeloma (RRMM), yet head-to-head trials against many commonly used lenalidomide-refractory regimens are not available. This study by...
Read More
Hagen Kennecke, a medical oncologist and professor of medicine at...
Read More
Dr. Hagen Kennecke discusses the use of cabozantinib in the...
Read More
Tony and his best friend, Michael, discuss Tony’s journey with...
Read More
Samantha Shenoy, MS, MSN, ACNP-BC, provides findings on the long-term...
Read More
Tony, who underwent CAR-T therapy for his multiple myeloma, shares...
Read More
Dr. Vijayvergia emphasizes the importance of patient-physician communication and patient...
Read More
Mary Steinbach, DNP, APRN, and Eliza Parkin, NP, discuss the...
Read More
Tony, who was diagnosed with multiple myeloma in 2013, and...
Read More©2026 Oncology Matrix. All Rights Reserved.
